Skip to main content
Premium Trial:

Request an Annual Quote

Disclosure Woes

A new analysis published in the Archives of Internal Medicine says that the medical journal disclosure policy that requires a note at the end of papers listing any relationships the authors have with industry isn't working all that well, writes Katherine Hobson in the Wall Street Journal's Health Blog. The authors looked at physician payment data from five different orthopedic device companies and compared them to the disclosures in the articles. They followed 41 clinicians who received at least $1 million in 2007. "Researchers found that even with articles where a physician was listed as a prominent author, 46 percent of the papers didn't disclose the industry relationship," Hobson says. "For articles with a subject matter directly or indirectly related to the company paying the author, only half disclosed the relationship." The researchers say it may be time for journals to start doing spot checks in order to verify the information they're getting — something that's going to get easier soon. In 2013, Hobson says, a provision of the new health care law will require industry to report all physician payments over $10 to a central database.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.